Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Eva Koziolová"'
Autor:
M. Netopilík, Assala Al Samad, F. El Omar, Benjamin Nottelet, Youssef Bakkour, Jean Coudane, Eva Koziolová, Tomáš Etrych, Audrey Bethry
Publikováno v:
Journal of materials chemistry B
Journal of materials chemistry B, Royal Society of Chemistry, 2016, 4, pp.6228-6239. ⟨10.1039/c6tb01841f⟩
Journal of materials chemistry B, Royal Society of Chemistry, 2016, 4, pp.6228-6239. ⟨10.1039/c6tb01841f⟩
International audience; The development of flexible drug delivery systems that can be tuned as a function of the drug to bedelivered and of the target disease is crucial in modern medicine. For this aim, novel amphiphilic poly-(e-caprolactone)-g-poly
Publikováno v:
Scopus-Elsevier
Inflammation is a vital defense mechanism of living organisms. However, persistent and chronic inflammation may lead to severe pathological processes and evolve into various chronic inflammatory diseases (CID), e.g. rheumatoid arthritis, multiple scl
Autor:
Sergey K. Filippov, Ekaterina A. Lomkova, Petr Chytil, Christine M. Papadakis, Eva Koziolová, Bart-Jan Niebuur, Natalya S. Vishnevetskaya, Tomáš Etrych
Publikováno v:
Colloid and Polymer Science. 295:1313-1325
In the present paper, we address the question to which extent the critical micellar concentration (cmc) value can be varied for clinically related drug delivery carriers if all crucial parameters needed for successful drug delivery are already preset
Autor:
Tomáš Etrych, Kenji Tsukigawa, Eva Koziolová, Jun Fang, Petr Chytil, Karel Ulbrich, Hiroshi Maeda, Mamoru Haratake, Hideaki Nakamura
Publikováno v:
Molecular Pharmaceutics. 13:4106-4115
Many conjugates of water-soluble polymers with biologically active molecules were developed during the last two decades. Although, therapeutic effects of these conjugates are affected by the properties of carriers, the properties of the attached drug
Publikováno v:
Molecular pharmaceutics. 16(8)
N-(2-Hydroxypropyl)methacrylamide copolymer conjugates of pirarubicin (THP), P-THP, accumulates selectively in solid tumor tissue by the enhanced permeability and retention (EPR) effect. Despite of high accumulation in solid tumors, some macromolecul
Autor:
Tomas Eckschlager, Ladislav Sivák, Lucie Cuchalová, Jan Hraběta, Zuzana Hvězdová, Eva Koziolová, Karel Ulbrich, Tomáš Etrych, Vladimir Subr, Olga Janoušková
Publikováno v:
Journal of Controlled Release. 233:136-146
Water-soluble N -(2-hydroxypropyl)methacrylamide copolymer conjugates bearing the anticancer drugs doxorubicin (Dox) or pirarubicin (THP), P-gp inhibitors derived from reversin 121 (REV) or ritonavir (RIT)), or both anticancer drug and P-gp inhibitor
Autor:
Daniela Machová, Robert Pola, Michal Pechar, Olga Janoušková, Sergey K. Filippov, Petr Chytil, Vladimir Subr, Tomáš Etrych, Eva Koziolová, Richard Laga
Publikováno v:
Journal of Materials Chemistry B. 4:7620-7629
We describe design, synthesis, physico-chemical characterization and preliminary biological evaluation of micelle-forming polymer drug conjugates with controlled drug release intended for tumor treatment. The structure of the conjugates was designed
Autor:
Lenka Kotrchová, Libor Kostka, Benjamin Nottelet, Rafał Konefał, Eva Koziolová, Vladimir Subr, Tomáš Etrych
Publikováno v:
Biomacromolecules
Biomacromolecules, American Chemical Society, 2018, 19 (10), pp.4003-4013. ⟨10.1021/acs.biomac.8b00973⟩
Biomacromolecules, American Chemical Society, 2018, 19 (10), pp.4003-4013. ⟨10.1021/acs.biomac.8b00973⟩
We developed a new simplified method for the synthesis of well-defined linear, diblock, or starlike N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer drug carriers using controlled reversible addition-fragmentation chain transfer polymerization.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235b4b4537400699c2d43e5f9da119b6
https://hal.umontpellier.fr/hal-02385386
https://hal.umontpellier.fr/hal-02385386
Autor:
Kristýna Venclíková, Eva Koziolová, Petr Chytil, Daniela Machová, Olga Janoušková, Tomáš Etrych
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 131
Ritonavir (RIT) is a widely used antiviral drug that acts as an HIV protease inhibitor with emerging potential in anticancer therapies. RIT causes inhibition of P-glycoprotein, which plays an important role in multidrug resistance (MDR) in cancer cel
Publikováno v:
Scopus-Elsevier
ResearcherID
ResearcherID
Anthracyclines, e.g. doxorubicin, pirarubicin, are widely used as cytostatic agents in the polymer nanotherapeutics designed for the highly effective antitumor therapy with reduced side effects. However, their precise dosage scheme needs to be optimi